5 completed, 2 unknown, 1 active not recruiting, 1 terminated. 9 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 7 | Completed 4, Unknown 2, Active not recruiting 1 |
Follow Color Vision Defects: new trials by email Literature Review of Color Vision Defects trials Research Report on Color Vision Defects
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient-centered Modular CBT for CPTSD: A Randomised Controlled Pilot Study Psychotherapy - Complex Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | Danish Veterans Centre | 60 | 2021-01-05 | 2025-04-02 |
| Gene Therapy for Achromatopsia (CNGA3) adeno-associated virus vector AAV- CNGA3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 11 | 2019-08-12 | 2022-12-01 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) AGTC-402 - Achromatopsia | Phase 1 / Phase 2 | Unknown | Beacon Therapeutics | 24 | 2017-08-03 | 2022-07-22 |
| Gene Therapy for Achromatopsia (CNGB3) AAV - CNGB3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 23 | 2017-01-16 | 2023-03-08 |
| Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) rAAV2tYF-PR1.7-hCNGB3 - Achromatopsia | Phase 1 / Phase 2 | Unknown | Beacon Therapeutics | 32 | 2016-04-11 | 2022-07-22 |
| Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia rAAV.hCNGA3 - Achromatopsia | Phase 1 / Phase 2 | Active not recruiting | STZ eyetrial | 13 | 2015-11-01 | 2024-04-18 |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
| CNTF Implants for CNGB3 Achromatopsia NT-501 CNTF-releasing implant - Eye Disease, Achromatopsia | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2012-07-01 | 2016-11-21 |
Eye Diseases (2) · Corticobasal Degeneration (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pick Disease of the Brain (1) · Primary Progressive Nonfluent Aphasia (1) · Sensation Disorders (1) · Signs and Symptoms (1) · Supranuclear Palsy, Progressive (1) · Vision Disorders (1)
Cone Dystrophy (9) · Eye Diseases, Hereditary (9) · Pathological Conditions, Signs and Symptoms (9) · Nervous System Diseases (8) · Neurologic Manifestations (8) · Sensation Disorders (8) · Signs and Symptoms (8) · Vision Disorders (8) · Eye Diseases (7) · Brain Diseases (2) · Central Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Aphasia (1) · Aphasia, Primary Progressive (1) · Basal Ganglia Diseases (1)
Psychotherapy (1) · TPI-287 (1) · gosuranemab (1)
Beacon Therapeutics (2) · MeiraGTx UK II Ltd (2) · University of California, San Francisco (2) · Danish Veterans Centre (1) · National Eye Institute (NEI) (1) · STZ eyetrial (1)
United States (7) · United Kingdom (2) · Denmark (1) · Germany (1) · Israel (1)
Adam Boxer, MD, PhD (2) · David Jacobs, MD, MBA (2) · Dominik Fischer, Prof. (1) · James Bainbridge (1) · James Bainbridge, Prof (1) · Paul A Sieving, MD, PhD (1) · Sofie Folke, PhD (1)
PMID 25205868, PMID 30194931, PMID 31710340, PMID 32352493, PMID 34006508, PMID 37172884
2014 (1), 2016 (1), R24EY022023 (1)